Novartis ADR

Operating internationally, Novartis is a pharmaceutical company that develops, manufactures, and markets ophthalmic products, biosimilars, branded and generic prescription drugs, and active pharmaceutical ingredients (APIs). Founded in 1996 as the result of a merger between Ciba-Geigy and Sandoz, the company has its headquarters in Basel, Switzerland. Novartis mainly focuses on treatments for health problems related to cancer, cardiometabolism, immunology and dermatology, neuroscience, ophthalmology, and respiratory diseases. The company operates through two divisions: Innovative Medicines and Sandoz. Novartis' Innovative Medicines division is comprised of two business units: Novartis Pharmaceuticals and Novartis Oncology. The company's Innovative Medicines division develops and produces patent-protected prescription medicines for cancer, blood pressure, and other ailments. Through the Sandoz division, Novartis develops and produces generic pharmaceuticals and biosimilars. Stock for Novartis is listed on the NYSE under the ticker NVS. The company also operates the Novartis Institutes for BioMedical Research (NIBR), which focus on discovering new drugs that can change the practice of medicine. Novartis operates six research campuses and has 5,600 employees dedicated to discovering new treatments. As of December 2021, Novartis products are used by nearly 800 million people globally, and the company employs approximately 108,000 people around the world. Find NVS share price updates and additional relevant information by adding it to your eToro watchlist.